alogliptin and metformin hydrochloride
alogliptin and metformin hydrochloride is listed in the FDA National Drug Code directory with 13 NDC codes, marketed under brand names including KAZANO, alogliptin and metformin hydrochloride. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- alogliptin and metformin hydrochloride
- Brand Names
- KAZANO, alogliptin and metformin hydrochloride
- Application Number
- NDA203414
- Sponsor
- Takeda Pharmaceuticals America, Inc.
- NDC Codes
- 13
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- ALOGLIPTIN BENZOATE, METFORMIN HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE Alogliptin and metformin HCl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin and metformin HCl tablets are a combination of alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor and metformin, a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin and metformin HCl tablets should not be used in patients with type 1 diabetes mellitus.